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Background: Oral cholinesterase inhibitors at doses efficacious for the treatment of Alzheimer’s 
disease (AD) are often prematurely discontinued due to gastrointestinal side effects. In controlled 
clinical trials, transdermal rivastigmine demonstrated less such effects at similar efficacy. The 
current study aimed to verify the validity of this data in daily practice.
Methods: This was a prospective, multicenter, observational study on transdermal rivastigmine 
in Germany. Eligible patients were those with AD who had not yet been treated with rivastigmine. 
Outcome measures were changes in clock-drawing test, Mini-Mental State Examination 
(MMSE), Caregiver Burden Scale, Clinical Global Impression (CGI), physicians’ assessments 
of tolerability, and the incidence of adverse events (AEs) over 4 months of treatment.
Results: In 257 centers 1113 patients were enrolled; 614 women and 499 men, mean age 76.5 
years. In 58% of patients AD was treated for the first time and in 42% therapy was switched to 
transdermal rivastigmine, mostly due to lack of tolerability (13.6%) or effectiveness (26.9%). 
After 4 months, 67.4% of patients were on the target dose of 9.5 mg/day and 21.8% were still on 
4.6 mg/day. MMSE significantly improved in patients with and without pretreatment (∆MMSE, 
0.9 ± 3.4 and 0.8 ± 3.4, respectively, both P , 0.001); the CGI score improved in 60.9% and 
61.3% of patients, respectively. Overall 11.7% of patients had AEs, mainly affecting the skin 
or the gastrointestinal tract; in 1.1% of cases AEs were serious; 14.7% of patients discontin-
ued therapy, 6.0% due to AEs. With rivastigmine treatment the percentage of patients taking 
psychotropic comedication decreased, particularly in first-time treated rivastigmine patients 
(from 27.1% to 22.6%; P , 0.001).
Conclusion: Results were in line with data from controlled clinical trials. Switching from any 
other oral acetylcholinesterase inhibitor to transdermal rivastigmine may improve cognition.
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Introduction
In Germany, about one million people suffer from dementia,1,2 with 50% to 70% of 
these due to Alzheimer’s disease (AD). Based on demographic changes, AD prevalence 
is predicted to increase by 50% in the next 25 years. The primary objective of current 
pharmacological AD therapy is to slow down disease progression and to preserve the 
capability for activities of daily life.3
Cholinesterase (CHE) inhibitors are a mainstay in the treatment of mild to 
moderate AD. Only oral treatments were available until rivastigmine (Exelon®; 
Novartis, Basel, Switzerland) was approved as the first transdermal antidementia 
drug in 2007. Transdermal patches provide continuous drug delivery and maintain 
rivastigmine concentrations within the optimal therapeutic window avoiding the 
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peaks and troughs associated with oral administration. The 
rivastigmine patch was demonstrated to be as efficacious as 
the highest oral doses and with approximately three times 
fewer reports of gastrointestinal adverse events (AEs), 
such as nausea and vomiting.4 Moreover, the once-daily 
application of the patch is supposed to improve compliance 
with the recommended dosing regimen. Better compliance 
may increase effectiveness and reduce caregiver burden, 
institutionalization rate, and costs. Given these advantages, 
the rivastigmine patch may be superior to oral CHE inhibitors 
and may advance the treatment of AD long-term.5
However, patients in clinical trials are known not to be 
representative of the total target population. Selection bias is 
particularly caused by excluding patients who do not respond 
to existing first-line treatments. Therefore, the current study 
aimed to verify the external validity of clinical trial data on 
the efficacy and tolerability of transdermal rivastigmine under 
daily routine conditions in Germany. A subgroup analysis was 
undertaken to elucidate the role of previous and concomitant 
medication.
Methods
Study design
This was a prospective, multicenter, observational study on 
the effectiveness and tolerability of rivastigmine patch for the 
treatment of AD in everyday practice in Germany. For each 
eligible patient, physicians were requested to collect data 
immediately prior to and about 1 month and 4 months after 
treatment initiation. The study was conducted from January to 
October 2008 in compliance with the Declaration of Helsinki 
and all applicable legal requirements.
Patients
Outpatients with mild-to-moderate AD in conformity with 
the specification of the drug label were eligible if they had 
not previously been treated with rivastigmine. Patients had 
to be fully capable to contract and to make a decision about 
participation in the study. All included patients consented to 
the use of their pseudo-anonymized data.
Treatment
As this was an observational study there were no pro-
tocol instructions on treatment. The provided product 
information specified to use the 5 cm2 patch corresponding 
to an initial dose of 4.6 mg rivastigmine per 24 hours for 
a minimum of 4 weeks first and to change to the 10 cm2 
patch corresponding to the recommended effective dose of 
9.5 mg rivastigmine per 24 hours as tolerability allows.
Outcome measures
Effectiveness was evaluated based on (a) the Mini-Mental State 
Examination (MMSE), a brief 30-point screening instrument 
for cognitive impairment; (b) the clock-drawing test (CDT) 
to assess on a 7-point scale visual–spatial   construction, 
visual perception, and abstract conceptualization; (c) the 
Clinical Global Impression (CGI) of the patient as assessed 
on a 5-point scale by the attending physician; and (d) the 
caregivers’ quality of life on the Caregiver Burden Scale 
(CBS), parts A and B. Part A included six statements on the 
caregiver (maximum 30 points) and part B included seven 
statements on the caregiver–patient relationship (maximum 
35 points). Each statement was to be assessed on a 5-point 
scale with high scores representing high burden.
In addition, drug safety and tolerability were evaluated 
based on the monitoring of AEs and the physicians’ global 
tolerability assessment per patient. For an evaluation 
of treatment practice and compliance, daily doses, dose 
adjustments, concomitant and previous medications, and 
premature discontinuation of the rivastigmine patch were 
recorded.
Data analysis
Diseases were classified according to the International 
Classification of Diseases, version 10; medications according 
to the WHO Drug Dictionary as of March 1st 2007; and AEs 
according to the Medical Dictionary for Regulatory Activities, 
version 11.1. All patients who gave informed consent and 
started treatment with rivastigmine patch based on the 
recommendation of their physician entered the analysis. 
Descriptive data analyses were performed using summary 
statistics for categorical and quantitative data. Continuous 
data were described as median, means, standard deviation 
(SD), minimum, maximum, and 25th and 75th percentiles. 
Stratification and categorization were based on clinical 
criteria. In case of qualitative variables the absolute and 
relative frequencies were calculated. In stratified analyses 
percentages were given per category and stratum. Safety 
analyses included tabulation of type and frequency of AEs 
on a patient and event basis. The role of premedication for 
effectiveness and tolerability was examined by a subgroup 
analysis comparing outcomes in patients who had previously 
been treated with other antidementia drugs (pretreated) and 
patients who received rivastigmine as the first antidementia 
drug (first-time treated). For inferential statistics a two-sided 
t-test at a significance level of 0.05 was used. All analyses 
were conducted with SAS for Windows (version 9.1; SAS 
Institute, Cary, NC).
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Table 1 Demographics and disease characteristics in first-time 
and pretreated patients
First-time 
treated  
n = 638
Pretreated  
n = 457
P
Age (years) 76.7 (7.7) 76.2 (7.2) 0.2536
Sex 
• Male 
• Female
 
44.1% 
55.9%
 
45.7% 
54.3%
0.6250
AD due to iCD 10 
• Early onset AD 
• Late onset AD 
• AD NOS 
• Other
 
12.7% 
59.3% 
20.0% 
8.0%
 
13.3% 
64.8% 
16.1% 
5.8%
0.1345
Disease history (years) 
• AD 
• Dementia
 
0.6 (1.5) 
0.7 (1.6)
 
1.5 (1.9) 
1.7 (2.1)
 
,0.0001 
,0.0001
Housing conditions 
• Solitarily 
• With family 
• Homebound/assisted living
 
16.3% 
67.6% 
16.1%
 
9.4% 
79.4% 
11.2%
,0.0001
Abbreviations: AD, Alzheimer’s disease; ICD 10, International Classification of 
Diseases, version 10; NOS, not otherwise specified.
Results
Patient population
In 257 centers, 1113 patients, 614 women (55.2%) and 
499 men (44.8%), with a mean age of 76.5 ± 7.5 (SD) 
years were enrolled; in 12.9% of patients onset of AD was 
categorized as early and in 61.5% as late; for 18.3% onset was 
not specified and 8.8% of patients had additional diagnoses 
associated with dementia. Patients were diagnosed with AD 
on average 1.0 ± 1.7 years (mean ± SD) prior to the baseline 
visit and first dementia symptoms manifested 1.2 ± 1.9 years 
before. About 42% of patients were included in the pretreated 
group. The most common previous treatments were other 
CHE inhibitors (24.5%). About two thirds (64.2%) switched 
to the rivastigmine patch due to lack of efficacy and about 
one third (32.4%) due to lack of tolerability. At baseline, 
first-time treated, and pretreated subgroups were comparable 
in demographic characteristics, but the disease in pretreated 
patients was further advanced (Table 1).
Treatment practice and compliance
The study was completed by 92.8% of patients. The majority 
of these patients also attended both follow-up visits; 6.1% 
of patients attended one follow-up visit only and 1.1% of 
patients were lost to follow up without any post-treatment 
assessment. Patch treatment was discontinued within the 
4 month observation period by 164 (14.7%) patients, on 
average 91 ± 43 days after initiation, due to AEs (6.0%), lack 
of compliance (3.1%) and/or efficacy (1.8%), for unknown 
(3.3%) or other reasons (3.0%). In compliance with the 
product information, 95.6% of patients started treatment at 
the recommended initial dose of 4.6 mg/24 hours (Figure 1). 
In 62.3% of patients the dose was subsequently escalated 
to 9.5 mg/24 hours. In about one quarter of patients, the 
dose was not changed at all and 21.8% of patients remained 
on the low initial dose for the 4 month study period. For a 
minority of patients (2.7%) the dose was adjusted twice or 
decreased once.
At the initial visit, 29.0% of patients received 
comedication, most commonly antipsychotics (17.1%) and 
antidepressants (12.3%). The most frequently recorded 
antipsychotic drugs accounting for 86.3% of this drug class 
were risperidone, melperone, quetiapine, and pipamperone. 
Citalopram, mirtazapine, sertraline, and venlafaxine 
together accounted for 71.5% of all antidepressants given 
concomitantly. Within 4 months on transdermal rivastigmine, 
the proportion of patients taking psychotropic comedication 
overall decreased from 29.0% to 25.8% with 15.4% taking 
antipsychotics and 11% antidepressants; among these drug 
classes, greatest decreases showed pipamperone from 11.1% 
to 9.4% of patients and sertraline from 10.2% to 6.6% of 
patients, respectively.
Effectiveness
Patients showed no deterioration in disease-specific outcome 
measures. Between baseline and the end of the observation 
period (4 months), mean scores on the MMSE and the 
CDT significantly increased by 0.9 ± 3.4 (from 18.1 ± 5.7 
to 18.8 ± 5.9; P , 0.0001) and 0.3 ± 1.5 (from 3.2 ± 2.0 
to 3.5 ± 2.2; P , 0.0001), respectively. After 1 month, 
the attending physician rated the CGI in 50.9% of patients 
as better, in 45.6% as unchanged, and in 0.4% as worse 
(3.1% missing). After 4 months, the corresponding rates 
were 61.1%, 28.9%, and 3.1%, respectively (6.8% missing) 
(Figure 2). The mean CBS-A and -B scores significantly 
decreased by 0.9 ± 3.4 (from initially 18.4 ± 6.1 to 17.3 ± 5.9 
after 4 months; P , 0.0001) and 1.2 ± 3.4 (from initially 
15.8 ± 6.5 to 15.2 ± 6.1; P , 0.0001), respectively.
Tolerability and safety
After 1 month of treatment, physicians rated tolerability as 
very good or good in 93.7% of patients and poor in 2.8% of 
patients (3.5% unknown or missing). After 4 months, it was 
still good or very good in 86.6% of patients and poor in 5.9% 
of patients (7.6% unknown or missing) (Figure 3).
A total of 226 AEs were reported in 130 (11.7%) patients; 
of these, physicians deemed 166 at least possibly related to 
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Figure 1 Dosing practice at baseline, after 1 month, and after 4 months.
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Figure 2 Overall medical impression of the patient as assessed by the attending physician after 1 month and after 4 months.
rivastigmine, 26 of them being serious. Potentially related 
AEs occurred in 104 patients (9.4%): 58 patients (5.2%) 
had one; 32 patients (2.9%) two; ten patients (0.9%) three; 
three patients (0.3%) four; and one patient (0.1%) five 
such AEs.
The most frequent AEs were erythema and nausea, and 
the most frequently affected system organ classes were skin 
and subcutaneous tissue disorders, gastrointestinal, psychiat-
ric, and nervous system disorders (Table 2). More than half 
of the skin and subcutaneous tissue disorders occurred within 
the first 6 weeks of treatment. Psychiatric and nervous system 
disorders were less frequent than dermatological and gastro-
intestinal disorders, but these AEs were more often serious. 
Overall incidence rates of potentially rivastigmine-related 
AEs and serious AEs (SAEs) were 8.3% and 1.1% of 
patients, respectively. Severity was mild in 29.0%, moderate 
in 39.6%, and severe in 20.1% of AEs (11.2% missing). 
By the end of the study, patients had recovered from 72% 
and 61.6% of such AEs and SAEs, respectively, whereas 
18.9% of AEs and 11.5% of SAEs in a total of 19 patients 
had not resolved yet. One fatal SAE was deemed probably 
drug-related by the investigator, a completed suicide after 
hallucination of a 93-year-old female patient, 49 days after 
treatment initiation.
role of premedication
Pretreated as compared to first-time treated patients tended 
to escalate earlier to the target dose (after 1 month 61.2% 
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Figure 3 Tolerability as assessed by the attending physician after 1 month and after 4 months.
versus 54.5% on 9.5 mg/day), to remain longer in the trial 
(drop-out rates after 4 months, 5.6% versus 9.0%), and a 
higher proportion was on the target dose after 4 months 
(71.0% versus 64.9%), although none of these differences 
was actually significant. The decrease in the proportion 
of patients taking psychotropic comedication was more 
pronounced and significant in patients who had not been 
pretreated (from 27.1% to 22.6%; P , 0.001). MMSE and 
the CGI improved under rivastigmine, regardless of whether 
patients were pre- or first-time treated. Over 4 months, the 
MMSE changed by 0.8 ± 3.4 in pretreated and by 0.9 ± 3.4 
in first-time treated patients; the CGI improved in 61.3% 
and 60.9%, respectively (all P . 0.1).
Discussion
Rivastigmine was the first CHE inhibitor of which a patch 
  formulation was approved for the treatment of mild to 
moderate AD.4,6 According to results from a double-blind, 
randomized, active- and placebo-controlled clinical trial, 
the Investigation of transDermal Exelon in ALzheimer’s 
disease (IDEAL), transdermal rivastigmine provides 
superior tolerability at noninferior efficacy as compared 
to the capsule formulation. Through improved patients’ 
compliance and adherence this may increase drug 
effectiveness. However, clinical trial data need to be verified 
in daily practice as external validity might be limited, 
in particular due to selection bias caused by inclusion 
and exclusion criteria.
In the IDEAL trial inclusion criteria were 50 to 85 years 
of age, an MRI-confirmed AD diagnosis not older than 1 year 
Table 2 incidence of AEs and SAEs (by system organ class and 
preferred term) that physicians deemed at least possibly related to 
rivastigmine, (preferred terms listed only if total incidence $ 0.5%)
AE SAE Total
n % n % n %
MedDrA system organ class
•  preferred term
Total 1113 100 1113 100 1113 100
Skin and subcutaneous  
tissue disorders
65 5.8 – – 65 5.8
•  Dermatitis contact 10 0.9 – – 10 0.9
•  Erythema 28 2.5 – – 28 2.5
•  Pruritus 10 0.9 – – 10 0.9
Gastrointestinal disorders 34 3.1 1 0.1 35 3.1
•  Nausea 19 1.7 – – 19 1.7
•  Vomiting 10 0.9 – – 10 0.9
Psychiatric disorders 19 1.7 13 1.2 32 2.9
•  restlessness 7 0.6 1 0.1 8 0.7
Nervous system disorders 10 0.9 4 0.4 14 1.3
•  Dizziness 8 0.7 1 0.1 9 0.8
General disorders and  
administration site conditions
7 0.6 2 0.2 9 0.8
Cardiac disorders 1 0.1 2 0.2 3 0.3
Metabolism and nutrition  
disorders
– – 2 0.2 2 0.2
injury, poisoning,  
and procedural complications
– – 1 0.1 1 0.1
renal and urinary disorders – – 1 0.1 1 0.1
Ear and labyrinth disorders 1 0.1 0 0 1 0.1
immune system disorders 1 0.1 – – 1 0.1
investigations 1 0.1 – – 1 0.1
respiratory, thoracic, and  
mediastinal disorders
1 0.1 – – 1 0.1
Total 140 12.6 26 2.3 166 14.9
Abbreviations: AE, adverse event; SAE, serious adverse event; MedDrA, Medical 
Dictionary for Regulatory Activities.
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10%. Apart from these administration site reactions, which 
were an endpoint rather than an AE in IDEAL, nausea and 
vomiting were also the most frequently observed single AEs 
in common practice.
Our results are also in line with those of several open-label 
studies demonstrating benefits from switching AD therapy 
to rivastigmine after other CHE inhibitors and particularly 
donepezil have failed in terms of efficacy or tolerability.8,9 
An additional and rather specific benefit associated with the 
use of rivastigmine might be the reduction of psychotropic 
comedication. This may be a result of increased cholinergic 
function in the human limbic system and thalamus due to 
the inhibition of both acetylcholinesterase and butyryl-
cholinesterase by rivastigmine. The dual inhibition may 
contribute to a drug-saving effect as butyrylcholinesterase 
activity increases with AD progression and severity. Such 
a drug saving effect was first described in another observa-
tional study (EXALAN) using oral rivastigmine in a similar 
population and over a similar period of time.10 In the current 
study, such a drug-sparing effect was also detectable with 
the transdermal formulation, although it was less striking. 
However, the effect sizes observed in both studies are not 
directly comparable as in the current study neither patients 
had to take any psychoactive medication for inclusion (as in 
EXALAN) nor were dose reductions recorded. In EXALAN, 
patients reducing psychotropic medication were shown to 
also gain the largest cognitive benefit from rivastigmine. 
Based on the small sample size, this could not be exam-
ined in the current study, but the proportion of patients 
who discontinued psychotropic comedication as well as 
the clinical benefit tended both to be higher in first-time 
treated as compared to pretreated patients. Whether such a 
drug sparing effect is indeed related to premedication or to 
different disease characteristics in both subgroups remains 
to be elucidated.
Conclusion
In conclusion, our study confirmed the tolerability and 
effectiveness of transdermal rivastigmine in daily practice. 
Interestingly, the number of adverse events and the magnitude 
of cognitive improvement were similar in first- and pretreated 
patients and among subgroups of the latter. This further 
supports consideration of transdermal rivastigmine when 
other treatments have failed due to lack of either efficacy or 
tolerability. Whether rivastigmine has a direct drug-sparing 
effect on psychotropic comedication as seen in this and 
another observational study deserves further investigation in 
controlled clinical trials.
prior to inclusion, MMSE baseline scores between 10 and 20, 
and patients had to live with someone in the community or 
to be in daily contact with a caregiver. Exclusion criteria 
were advanced, severe, progressive, or unstable disease, an 
unconfirmed AD diagnosis, or another AD treatment within 
4 weeks prior to randomization.4,6 Not all of these data were 
collected in the current study, but solely based on the age 
and MMSE criteria about 64% of the patient population – 
although similar in size and likely representative of the total 
target population in Germany – would have been excluded. 
This is much higher than one might expect from the overall 
screening failure rate of 18.4% in IDEAL if both populations 
were the same. Consequently, the patch-treated patients in this 
study were slightly older (76.5 ± 7.5 years versus 73.6 ± 7.9 
years), significantly more often male (44.8% versus 32.0%), 
and had lower MMSE baseline scores (18.1 ± 5.7 versus 
16.5 ± 3.0).
However, despite those differences in patient populations, 
effectiveness shown in this trial was well in line with cor-
responding results of IDEAL: MMSE scores significantly 
increased on average by 0.7 (0.9 in the first-time treated 
group) over 4 months versus 0.9 in the corresponding treat-
ment arm of IDEAL.4,6 CDT scores increased in both studies 
by 0.3. Percentages of patients with improved CGI treated 
with transdermal rivastigmine were higher in the current 
study but this comparison is biased as the assessment method 
was different. CBS was not used in IDEAL, however decreas-
ing scores in both Parts A and B in this study are in line with 
the distinct caregiver preference for the patch relative to 
capsules observed in IDEAL.7
In the current study, safety and tolerability of transdermal 
rivastigmine appeared even more favorable; however this 
has to be taken with caution. The lower discontinuation 
rate of 14.7% versus 21.8% in IDEAL might be due to the 
2 months shorter treatment duration and the less rigid dose 
escalation to 9.5 mg/day after the first month. Actually, under 
routine conditions about one fifth of patients still remained 
on the initial dose of 4.6 mg/day over 4 months. By contrast, 
the difference in the percentage of patients discontinuing 
due to an AE (6.0% versus 9.6%) is quite small. However, 
one has to bear in mind that the AE monitoring in a GCP-
compliant clinical trial is much closer and not comparable 
to that of the current observational study. This is clearly 
reflected by recording only 12% of patients having any 
AE whereas in the corresponding treatment arm of IDEAL 
51% of patients had any AE. In IDEAL, the most common 
AEs were nausea (7.2%) and vomiting (6.2%), whereas the 
incidence of severe skin irritation was stated to be less than 
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